Wave Life Sciences Ltd.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $42.7M | $108.3M | $113.3M | $3.6M | $41.0M |
| Operating income | -$215.4M | -$110.4M | -$68.0M | -$162.7M | -$127.0M |
| Operating expenses | $258.1M | $218.7M | $181.3M | $166.4M | $168.0M |
| Cash from operations | -$187.5M | -$151.0M | -$19.4M | -$127.8M | -$89.0M |
| Capital expenditure | $718,000 | $938,000 | $1.1M | $1.4M | $560,000 |
| Free cash flow | -$188.2M | -$152.0M | -$20.5M | -$129.1M | -$89.6M |
| Total assets | $638.5M | $352.2M | $274.9M | $146.4M | $207.0M |
| Total liabilities | $112.3M | $134.8M | $227.4M | $183.6M | $166.6M |
Shares outstanding 192.4M · Free float 58.6%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.